U.S., April 17 -- ClinicalTrials.gov registry received information related to the study (NCT07534033) titled 'Phase II Clinical Study of Probiotic LR607 in Patients With Non-Small Cell Lung Cancer' on Dec. 11, 2025.
Brief Summary: The goal of this clinical trial is to understand whether Lactobacillus rhamnosus LR607 can enhance neoadjuvant chemoimmunotherapy for adult patients with non-small cell lung cancer. It will also evaluate the safety of LR607. The main questions it aims to answer include:
Can LR607 improve the major pathological response of neoadjuvant chemoimmunotherapy? What is the relationship between LR607 combined with neoadjuvant chemoimmunotherapy and treatment-related adverse reactions? What changes occur in the gut microb...